tirzepatide retinopathy Linked to Reduced Risk of Diabetic Among Obese Diabetics, Suggests Study At a glance factsheet: Tirzepatide

Centers for Diseases Control and Prevention

Efficacy and Safety of Oral Semaglutide in the Management of Diabetes and Obesity: A Comprehensive Meta-analysis of Real-world Evidence

Addressing low-grade inflammation associated with obesity, reducing cardiovascular burden, and achieving overall health improvement remain significant unmet needs in PsD

Starting at a microdose lets the body gently adjust to the medication, often eliminating the need for aggressive symptom management

In the phase III STEP 6 trial conducted in Japan and South Korea, semaglutide 2.4 mg resulted in a mean percentage change in body weight from baseline to week 68 of -13.2% (standard error [SE] 0.5), compared with -2.1% (SE 0.8) achieved with placebo, corresponding to a between-group difference of -11.1% (95% confidence interval [CI], -12.9 to -9.2) using the treatment policy estimand

LegitScript verifies that they operate under US law, use real doctors, and fill prescriptions through state-licensed pharmacies